TD
MCID: TRD006
MIFTS: 61

Tardive Dyskinesia (TD)

Categories: Gastrointestinal diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tardive Dyskinesia

MalaCards integrated aliases for Tardive Dyskinesia:

Name: Tardive Dyskinesia 58 77 54 55 30 74
Neuroleptic-Induced Tardive Dyskinesia 74
Lingual-Facial-Buccal Dyskinesia 74
Drug-Induced Tardive Dyskinesia 74
Linguofacial Dyskinesia 54
Tardive Oral Dyskinesia 54
Tardive Dystonia 54
Td 54

Characteristics:

OMIM:

58
Inheritance:
autosomal recessive predisposition


HPO:

33
tardive dyskinesia:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 58 272620
MedGen 43 C0686347
SNOMED-CT via HPO 70 258211005

Summaries for Tardive Dyskinesia

NIH Rare Diseases : 54 Tardive dyskinesia is a neurological movement disorder that is caused by the long-term use of a certain type of medications called neuroleptics. Neuroleptic drugs are usually prescribed for psychiatric conditions, although they may be used to treat gastrointestinal or neurological conditions in some cases. Tardive dyskinesia is primarily characterized by repetitive involuntary movements of the jaw, lips and tongue such as grimacing; sticking out the tongue; and smacking, puckering and pursing the lips. Some affected people may also experience involuntary rapid, jerking movements (chorea) or slow, writhing movements (athetosis) of the arms and/or legs. It is unclear why some people who take neuroleptic medications develop these symptoms while others do not. Treatment for this condition varies but may include stopping or minimizing the use of neuroleptic drugs and/or taking additional medications to to reduce the severity of the symptoms.

MalaCards based summary : Tardive Dyskinesia, also known as neuroleptic-induced tardive dyskinesia, is related to neuroleptic malignant syndrome and schizophrenia, and has symptoms including myoclonus and spasmodic torticollis. An important gene associated with Tardive Dyskinesia is NQO1 (NAD(P)H Quinone Dehydrogenase 1), and among its related pathways/superpathways are Glucose / Energy Metabolism and Monoamine GPCRs. The drugs Dopamine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include tongue, brain and eye, and related phenotypes are akathisia and tardive dyskinesia

OMIM : 58 Tardive dyskinesia is a debilitating motor disorder manifest as hyperkinetic, involuntary, repetitive movements predominantly of the orofacial region. It is a complication of treatment with so-called typical antipsychotic or neuroleptic agents, such as chlorpromazine or haloperidol, and is estimated to occur in 20 to 30% of chronic schizophrenics on long-term treatment (Thelma et al., 2008). (272620)

NINDS : 55 Tardive dyskinesia is a neurological syndrome caused by the long-term use of neuroleptic drugs. Neuroleptic drugs are generally prescribed for psychiatric disorders, as well as for some gastrointestinal and neurological disorders. Tardive dyskinesia is characterized by repetitive, involuntary, purposeless movements. Features of the disorder may include grimacing, tongue protrusion, lip smacking, puckering and pursing, and rapid eye blinking. Rapid movements of the arms, legs, and trunk may also occur. Involuntary movements of the fingers may be present.

Wikipedia : 77 Tardive dyskinesia (TD) is a disorder that results in involuntary, repetitive body movements. This may... more...

Related Diseases for Tardive Dyskinesia

Diseases related to Tardive Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Related Disease Score Top Affiliating Genes
1 neuroleptic malignant syndrome 30.6 CYP2D6 DRD2
2 schizophrenia 30.1 COMT CYP1A2 CYP2D6 DRD2 DRD3 HTR2A
3 mood disorder 30.0 COMT DRD2 DRD3 HTR2A
4 bipolar i disorder 29.9 COMT HTR2A
5 bipolar disorder 29.7 COMT DRD2 DRD3 HTR2A
6 schizoaffective disorder 29.6 COMT DRD2 DRD3 HTR2A
7 substance abuse 29.6 COMT CYP2D6 DRD2 DRD3
8 megacolon 29.6 DRD2 HTR2A
9 disease of mental health 29.5 COMT CYP2D6 DRD2 DRD3 HTR2A
10 major depressive disorder 29.4 COMT CYP2D6 DRD2 DRD3 HTR2A
11 anxiety 29.0 COMT CYP1A2 CYP2D6 HTR2A
12 attention deficit-hyperactivity disorder 28.9 COMT CYP2D6 DRD2 DRD3 HTR2A
13 dystonia 10.8
14 depression 10.7
15 movement disease 10.6
16 tremor 10.5
17 major affective disorder 4 10.4
18 major affective disorder 8 10.4
19 major affective disorder 7 10.4
20 major affective disorder 9 10.4
21 dementia 10.4
22 gilles de la tourette syndrome 10.4
23 choreatic disease 10.3
24 alzheimer disease 10.3
25 aging 10.3
26 diabetes mellitus 10.3
27 hypothyroidism 10.3
28 drug induced dyskinesia 10.3
29 impulse control disorder 10.2 DRD2 DRD3
30 galactorrhea 10.2 CYP2D6 DRD2
31 lymphatic malformation 5 10.2
32 graves disease 1 10.2
33 alacrima, achalasia, and mental retardation syndrome 10.2
34 neuropathy 10.2
35 narcolepsy 10.2
36 pain - chronic 10.2
37 dysphagia 10.2
38 schizophreniform disorder 10.1 COMT DRD2
39 migraine without aura 10.1 DRD2 DRD3
40 oppositional defiant disorder 10.1 COMT DRD2
41 alexithymia 10.1 COMT DRD2
42 opiate dependence 10.1 DRD2 DRD3
43 opioid addiction 10.1 COMT DRD2
44 traumatic brain injury 10.1 COMT DRD2
45 brain injury 10.1 COMT DRD2
46 gastroparesis 10.1 CYP2D6 DRD2
47 antisocial personality disorder 10.1 COMT DRD2
48 restless legs syndrome 10.0 DRD2 DRD3
49 amelogenesis imperfecta, type ib 10.0 CYP1A2 CYP2D6
50 toxicity or absent response to clozapine 10.0 COMT CYP1A2

Comorbidity relations with Tardive Dyskinesia via Phenotypic Disease Network (PDN): (show all 16)


Acute Cystitis Alzheimer Disease
Anxiety Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Dysthymic Disorder Esophagitis
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Paranoid Schizophrenia
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophrenia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Tardive Dyskinesia:



Diseases related to Tardive Dyskinesia

Symptoms & Phenotypes for Tardive Dyskinesia

Human phenotypes related to Tardive Dyskinesia:

33
# Description HPO Frequency HPO Source Accession
1 akathisia 33 HP:0031943
2 tardive dyskinesia 33 HP:0040141

Symptoms via clinical synopsis from OMIM:

58
Neuro:
akathisia
tardive dyskinesia
repetitive rapid body movements
chewing movements
oral-lingual-buccal dyskinesia
more
Misc:
complication of treatment with neuroleptic agents

Clinical features from OMIM:

272620

UMLS symptoms related to Tardive Dyskinesia:


myoclonus, spasmodic torticollis

MGI Mouse Phenotypes related to Tardive Dyskinesia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 COMT CYP1A2 DRD2 DRD3 HSPG2 HTR2A
2 cardiovascular system MP:0005385 9.63 COMT CYP1A2 DRD2 DRD3 HSPG2 SOD2
3 homeostasis/metabolism MP:0005376 9.5 COMT CYP1A2 DRD2 DRD3 HSPG2 NQO1
4 liver/biliary system MP:0005370 8.92 CYP1A2 DRD2 HSPG2 SOD2

Drugs & Therapeutics for Tardive Dyskinesia

Drugs for Tardive Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 62-31-7, 51-61-6 681
2
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
3
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
4
Zolpidem Approved Phase 4 82626-48-0 5732
5
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
6
Promethazine Approved, Investigational Phase 4 60-87-7 4927
7
tannic acid Approved Phase 4 1401-55-4
8
Amisulpride Approved, Investigational Phase 4 71675-85-9, 53583-79-2 2159
9
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
10
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
11
Galantamine Approved Phase 4 357-70-0 9651
12
Lithium carbonate Approved Phase 4 554-13-2
13
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
14
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
15
Nicotine Approved Phase 4 54-11-5 942 89594
16
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
17
Metoclopramide Approved, Investigational Phase 4,Phase 2 364-62-5 4168
18
Tetrabenazine Approved, Investigational Phase 4,Phase 3,Phase 2 58-46-8 6018
19
Haloperidol Approved Phase 4 52-86-8 3559
20
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
21
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
22
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
23
Calcium Approved, Nutraceutical Phase 4,Phase 2 7440-70-2 271
24
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
25 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Dopamine agonists Phase 4,Phase 3,Phase 2
29 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Phase 2
30 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3,Phase 2
31 Serotonin Receptor Agonists Phase 4,Phase 3,Phase 2
32 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
36 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Phase 2
38 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
39 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 GABA Agonists Phase 4
41 GABA-A Receptor Agonists Phase 4
42 Hypnotics and Sedatives Phase 4
43 GABA Agents Phase 4
44 Omega 3 Fatty Acid Phase 4,Phase 2
45 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
46 Antiemetics Phase 4,Phase 2,Phase 1
47 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 1
48 Antidepressive Agents, Second-Generation Phase 4
49 Autonomic Agents Phase 4,Phase 2,Phase 1
50 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
2 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
3 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
4 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
5 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
6 Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4 risperidone;olanzapine
7 Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
8 Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features Completed NCT00202293 Phase 4 Olanzapine;Lithium;Chlorpromazine
9 The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia Completed NCT00495352 Phase 4 Hihg-doseNRT, Low-dose NRT, bupropion
10 Study of Vitamin D in the Severely Mentally Ill Completed NCT01169142 Phase 4
11 Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics Completed NCT00458211 Phase 4 ziprasidone
12 A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00206102 Phase 4 quetiapine fumarate;risperidone
13 Antipsychotic Discontinuation in Alzheimer's Disease Completed NCT00417482 Phase 4 risperidone
14 Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women Completed NCT01937234 Phase 4 Metoclopramide;Placebo
15 Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Recruiting NCT03891862 Phase 4 Valbenazine;Placebo oral capsule
16 The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Recruiting NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
17 Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates Recruiting NCT03495024 Phase 4 Varenicline
18 Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia Recruiting NCT03323437 Phase 4 Risperidone
19 Agents Intervening Against Delirium in Intensive Care Unit Recruiting NCT03392376 Phase 4 Haloperidol Injection
20 Addressing Involuntary Movements in Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
21 Aim to Reduce Movements in Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
22 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02274558 Phase 3 NBI-98854;Placebo
23 Piracetam for Treatment Tardive Dyskinesia Completed NCT00190008 Phase 3 piracetam
24 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Completed NCT02736955 Phase 3 Valbenazine
25 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02405091 Phase 3 NBI-98854
26 Extract of Ginkgo Biloba and Tardive Dyskinesia Completed NCT00672373 Phase 3 Extract of Ginkgo Biloba (EGb-761 capsules);Placebo
27 Levetiracetam Treatment of Tardive Dyskinesia Completed NCT00291213 Phase 3 levetiracetam;placebo
28 Xenazine in Late Dyskinetic Syndrome With Neuroleptics Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
29 A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia Completed NCT00210769 Phase 3 paliperidone ER Oros
30 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
31 Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type Completed NCT01438060 Phase 3 Aripiprazole (BMS-337039);Placebo
32 High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms Completed NCT00403546 Phase 3 Ziprasidone 80-160 mg/d;Placebo;Ziprasidone 160 mg/d
33 Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Recruiting NCT03176771 Phase 2, Phase 3 MT-5199;Placebo
34 Reducing Involuntary Movements in Tardive Dyskinesia Active, not recruiting NCT02198794 Phase 3 SD-809;Placebo
35 Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Not yet recruiting NCT03790345 Phase 2, Phase 3 Pyridoxine;Cobalamin;Placebo Oral Tablet
36 A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents Not yet recruiting NCT03813238 Phase 3 Deutetrabenazine;Placebo
37 Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Withdrawn NCT03254186 Phase 2, Phase 3 Propranolol Hydrochloride;Placebo Oral Tablet
38 Pyridoxal Kinase Activity in Tardive Dyskinesia Withdrawn NCT01908452 Phase 3 Pyridoxine
39 Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia Unknown status NCT00621634 Phase 2
40 Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia Unknown status NCT00331669 Phase 2
41 Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia Completed NCT01267188 Phase 2 NBI-98854
42 A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia Completed NCT02064010 Phase 2 SNC-102;Placebo
43 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Completed NCT01733121 Phase 2 NBI-98854;NBI-98854;Placebo
44 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) Completed NCT01688037 Phase 2 NBI-98854;NBI-98854;Placebo
45 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT01393600 Phase 2 NBI-98854;NBI-98854;Placebo
46 Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia Completed NCT00175955 Phase 2 Levetiracetam
47 Dysport for the Treatment of OMD Completed NCT01921270 Phase 1, Phase 2 Low Dose - AbobotulinumtoxinA
48 Heart Rate Variability in Response to Metformin Challenge Completed NCT02500628 Phase 2 Metformin
49 Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia Completed NCT00401089 Phase 1, Phase 2 Panax Ginseng
50 Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy Completed NCT01677377 Phase 2 Risperidone;RBP-7000

Search NIH Clinical Center for Tardive Dyskinesia

Genetic Tests for Tardive Dyskinesia

Genetic tests related to Tardive Dyskinesia:

# Genetic test Affiliating Genes
1 Tardive Dyskinesia 30

Anatomical Context for Tardive Dyskinesia

MalaCards organs/tissues related to Tardive Dyskinesia:

42
Tongue, Brain, Eye, Pineal, Testes, Bone, Globus Pallidus

Publications for Tardive Dyskinesia

Articles related to Tardive Dyskinesia:

(show top 50) (show all 2409)
# Title Authors Year
1
The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. ( 30583148 )
2019
2
67 Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder. ( 30859987 )
2019
3
77 Long-term Valbenazine Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder and Tardive Dyskinesia. ( 30859992 )
2019
4
Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors. ( 30623717 )
2019
5
38 Global Improvement and Patient Satisfaction: Results from a Long-term, Open-label, Rollover Study of Valbenazine in Tardive Dyskinesia. ( 30859966 )
2019
6
39 Long-term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia. ( 30859967 )
2019
7
41 A Modified Delphi Consensus Approach to Clinical Guidelines for Tardive Dyskinesia. ( 30859969 )
2019
8
45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study. ( 30859973 )
2019
9
46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study. ( 30859974 )
2019
10
62 Predictors of Tardive Dyskinesia in Psychiatric Patients Taking Concomitant Antipsychotics. ( 30859983 )
2019
11
Lithium monotherapy-induced tardive dyskinesia. ( 30321768 )
2019
12
Tardive Dyskinesia Should Not Be Overlooked. ( 30388034 )
2019
13
No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia. ( 30623492 )
2019
14
The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders. ( 30638073 )
2019
15
Tardive dyskinesia is associated with altered putamen Akt/GSK-3β signaling in nonhuman primates. ( 30675935 )
2019
16
Deutetrabenazine in the treatment of tardive dyskinesia. ( 30702019 )
2019
17
Antipsychotic-induced tardive dyskinesia: update on epidemiology and management. ( 30720484 )
2019
18
Valbenazine in the treatment of tardive dyskinesia. ( 30724115 )
2019
19
Reply to: Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review. ( 30783553 )
2019
20
Treatment Recommendations for Tardive Dyskinesia. ( 30791698 )
2019
21
The use of clozapine and clonazepam co-administration in the treatment of a severe tardive dyskinesia: A case report. ( 30834119 )
2019
22
6 Presence and Impact of Possible Tardive Dyskinesia in Patients Prescribed Antipsychotics: Results from the RE-KINECTStudy. ( 30859939 )
2019
23
34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities. ( 30859963 )
2019
24
35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia. ( 30859964 )
2019
25
Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia. ( 29433806 )
2018
26
Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies. ( 29427000 )
2018
27
Tardive dyskinesia responsive to deep brain stimulation. ( 29506398 )
2018
28
Effectiveness and Value of 2 Novel Treatments for Tardive Dyskinesia. ( 29913006 )
2018
29
What You Should Know About Tardive Dyskinesia: Screening, Causes, and New Treatment Options. ( 29505191 )
2018
30
Tardive dyskinesia: Epidemiology. ( 29433811 )
2018
31
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia. ( 29945944 )
2018
32
VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia. ( 29609698 )
2018
33
Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. ( 29557243 )
2018
34
Tardive Dyskinesia: Is Vitamin E Singing the Prostate Blues? ( 29701932 )
2018
35
Two New Drugs for Tardive Dyskinesia Hit the Market. ( 29369770 )
2018
36
Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia. ( 29667946 )
2018
37
Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. ( 29338466 )
2018
38
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. ( 29409162 )
2018
39
VMAT2 inhibitors for the treatment of tardive dyskinesia. ( 29433808 )
2018
40
Future directions in tardive dyskinesia research. ( 29433809 )
2018
41
Correction to: Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. ( 29524074 )
2018
42
Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. ( 29552749 )
2018
43
The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate. ( 29338294 )
2018
44
Altered serum levels of glial cell line-derived neurotrophic factor in male chronic schizophrenia patients with tardive dyskinesia. ( 29901253 )
2018
45
Vitamin E for antipsychotic-induced tardive dyskinesia. ( 29341067 )
2018
46
Reprint of: Clinical management of tardive dyskinesia: Five steps to success. ( 29519687 )
2018
47
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. ( 29795977 )
2018
48
Clinical risk factors for the development of tardive dyskinesia. ( 29439776 )
2018
49
Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. ( 29663328 )
2018
50
Resting-state Brain Activity Changes Associated with Tardive Dyskinesia in Patients with Schizophrenia: Fractional Amplitude of Low-frequency Fluctuation Decreased in the Occipital Lobe. ( 29909076 )
2018

Variations for Tardive Dyskinesia

Expression for Tardive Dyskinesia

Search GEO for disease gene expression data for Tardive Dyskinesia.

Pathways for Tardive Dyskinesia

Pathways related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1 12.11 CYP1A2 CYP2D6 NQO1 SOD2
2
Show member pathways
11.59 DRD2 DRD3 HTR2A
3
Show member pathways
11.33 CYP1A2 CYP2D6 NQO1
4
Show member pathways
11.28 COMT CYP1A2
5 11.22 CYP1A2 NQO1
6 11.21 CYP1A2 NQO1
7
Show member pathways
11.18 COMT CYP1A2 CYP2D6
8
Show member pathways
11.1 CYP1A2 CYP2D6
9 11.06 CYP1A2 CYP2D6
10 10.97 NQO1 SOD2
11 10.8 DRD2 DRD3
12
Show member pathways
10.73 COMT CYP1A2 CYP2D6 NQO1
13
Show member pathways
10.66 COMT CYP1A2 NQO1
14
Show member pathways
10.64 CYP1A2 CYP2D6
15 10.55 COMT NQO1

GO Terms for Tardive Dyskinesia

Cellular components related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle GO:0030139 9.26 DRD2 DRD3
2 dendrite GO:0030425 9.26 COMT DRD2 HTR2A NQO1
3 integral component of postsynaptic membrane GO:0099055 9.16 DRD2 HTR2A
4 dopaminergic synapse GO:0098691 8.62 DRD2 DRD3

Biological processes related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.98 CYP1A2 CYP2D6 NQO1 SOD2
2 aging GO:0007568 9.82 HTR2A NQO1 SOD2
3 response to organic cyclic compound GO:0014070 9.77 COMT CYP1A2 NQO1
4 response to ethanol GO:0045471 9.74 DRD2 DRD3 NQO1
5 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.7 DRD2 DRD3
6 circadian regulation of gene expression GO:0032922 9.7 DRD2 DRD3
7 xenobiotic metabolic process GO:0006805 9.7 CYP1A2 CYP2D6 NQO1
8 negative regulation of protein kinase B signaling GO:0051898 9.69 DRD2 DRD3
9 regulation of synaptic vesicle exocytosis GO:2000300 9.69 DRD2 HTR2A
10 visual learning GO:0008542 9.69 DRD2 DRD3
11 release of sequestered calcium ion into cytosol GO:0051209 9.68 DRD2 HTR2A
12 response to cocaine GO:0042220 9.68 DRD2 DRD3
13 positive regulation of cytokinesis GO:0032467 9.68 DRD2 DRD3
14 response to amphetamine GO:0001975 9.67 DRD2 DRD3
15 regulation of dopamine secretion GO:0014059 9.67 DRD3 HTR2A
16 response to morphine GO:0043278 9.67 DRD2 DRD3
17 negative regulation of blood pressure GO:0045776 9.66 DRD2 DRD3
18 arachidonic acid secretion GO:0050482 9.66 DRD2 DRD3
19 drug metabolic process GO:0017144 9.65 CYP1A2 CYP2D6
20 exogenous drug catabolic process GO:0042738 9.65 CYP1A2 CYP2D6
21 long-chain fatty acid biosynthetic process GO:0042759 9.64 CYP1A2 CYP2D6
22 superoxide metabolic process GO:0006801 9.64 NQO1 SOD2
23 temperature homeostasis GO:0001659 9.63 DRD2 HTR2A
24 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.63 DRD2 DRD3
25 dopamine receptor signaling pathway GO:0007212 9.62 DRD2 DRD3
26 negative regulation of protein secretion GO:0050709 9.62 DRD2 DRD3
27 synaptic transmission, dopaminergic GO:0001963 9.61 DRD2 DRD3
28 prepulse inhibition GO:0060134 9.61 DRD2 DRD3
29 positive regulation of renal sodium excretion GO:0035815 9.59 DRD2 DRD3
30 removal of superoxide radicals GO:0019430 9.58 NQO1 SOD2
31 G protein-coupled receptor internalization GO:0002031 9.58 DRD2 DRD3
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.56 DRD2 DRD3
33 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.55 DRD2 HTR2A
34 oxidative demethylation GO:0070989 9.54 CYP1A2 CYP2D6
35 heterocycle metabolic process GO:0046483 9.51 CYP1A2 CYP2D6
36 drug catabolic process GO:0042737 9.49 CYP1A2 CYP2D6
37 monoterpenoid metabolic process GO:0016098 9.48 CYP1A2 CYP2D6
38 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.46 DRD2 DRD3
39 negative regulation of dopamine receptor signaling pathway GO:0060160 9.43 DRD2 DRD3
40 acid secretion GO:0046717 9.4 DRD2 DRD3
41 regulation of locomotion involved in locomotory behavior GO:0090325 9.37 DRD2 DRD3
42 response to drug GO:0042493 9.35 COMT CYP1A2 DRD2 DRD3 HTR2A
43 behavioral response to cocaine GO:0048148 9.33 DRD2 DRD3 HTR2A
44 response to histamine GO:0034776 9.32 DRD2 DRD3
45 alkaloid metabolic process GO:0009820 9.26 CYP1A2 CYP2D6
46 dopamine metabolic process GO:0042417 8.8 COMT DRD2 DRD3

Molecular functions related to Tardive Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.73 CYP1A2 CYP2D6 NQO1 SOD2
2 monooxygenase activity GO:0004497 9.48 CYP1A2 CYP2D6
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.46 CYP1A2 CYP2D6
4 aromatase activity GO:0070330 9.4 CYP1A2 CYP2D6
5 adrenergic receptor activity GO:0004935 9.37 DRD2 DRD3
6 dopamine binding GO:0035240 9.32 DRD2 DRD3
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD2 DRD3
8 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD2 DRD3
9 superoxide dismutase activity GO:0004784 8.96 NQO1 SOD2
10 drug binding GO:0008144 8.92 CYP2D6 DRD2 DRD3 HTR2A

Sources for Tardive Dyskinesia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....